Please login to the form below

Not currently logged in
Email:
Password:

Santhera Pharmaceuticals

This page shows the latest Santhera Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

The US Food and Drug Administration (FDA) has received Santhera Pharmaceuticals (Santhera) and ReveraGen BioPharma’s completed rolling submission of a New Drug Application (NDA) for the priority review of vamorolone ... Completion of the vamorolone NDA

Latest news

  • Summit takes clinical trial participant search online Summit takes clinical trial participant search online

    Hopes to broaden reach of its Duchenne muscular dystrophy study

  • Santhera closer to filing for muscular dystrophy drug Santhera closer to filing for muscular dystrophy drug

    Catena/Raxone slows loss of lung function in late stage trial. New late stage data has put Santhera Pharmaceuticals on track to be file its drug to treat respiratory complications in ... The supportive data are "clearly supportive and establish the

  • Biovail exits Parkinson's collaboration

    Biovail is returning the rights to a late-stage Parkinson's disease drug candidate to the Swiss firm Santhera Pharmaceuticals. ... Biovail, which was recently acquired by Valeant Pharmaceuticals, is returning the rights to a late-stage Parkinson's

  • Next generation

    Adrenaclick (Sciele). Anaphylaxis. US. Bacitracin. (Fera Pharmaceuticals). Eye infections. US. Budesonide/formoterol fumarate. ... Biovail Corporation and Santhera Pharmaceuticals are developing fipamezole, an α-2 adrenergic receptor antagonist, for the

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    He has experience at ING BHF-Bank, BASF, Knoll and Abbott. Former CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO. ... Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Because health means everything...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...